Clinical studies recruiting near Barrie

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Phase 2 · SimcoDerm Medical and Surgical Dermatology Centre · Takeda · NCT07108283 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Royal Victoria Regional Health Centre · Hoffmann-La Roche · NCT06793215 A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Phase 2 · SimcoDerm Medical and Surgical Dermatology Centre · Takeda · NCT07244263 Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patie
Phase N/A · Royal Victoria Regional Health Centre · University Health Network, Toronto · NCT06877598 Eliciting Informed Goals of Care in Elderly Patients
NA · Royal Victoria Regional Health Centre · Royal Victoria Hospital, Canada · NCT06002113 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Royal Victoria Regional Health Centre · NRG Oncology · NCT05174169 A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Phase 4 · Barrie GI Associates Inc. · Takeda · NCT06095128 Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu
Phase 3 · Royal Victoria Regional Health Centre · Canadian Cancer Trials Group · NCT06182774 Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of
Phase 3 · Research Site · AstraZeneca · NCT06921785 Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2 · Research Site · AstraZeneca · NCT06526793 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Phase 2 · Royal Victoria Regional Health Centre · Canadian Cancer Trials Group · NCT05640999 A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treat
Phase 3 · Research Site · AstraZeneca · NCT06764875 Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · Oruka Therapeutics Investigative Site · Oruka Therapeutics, Inc. · NCT07474792 Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
Phase N/A · Royal Victoria Regional Health Centre · Ontario Clinical Oncology Group (OCOG) · NCT04797299 Study Looking at Biomarkers in Ovarian Cancer
NA · Royal Victoria Regional Health Centre · University Health Network, Toronto · NCT03419689 A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo
Phase N/A · Simcoderm Medical And Surgical Dermatology Centre /ID# 27683 · AbbVie · NCT07136467 CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee
NA · Royal Victoria Regional Health Centre · Sunnybrook Health Sciences Centre · NCT05828810 A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3 · Barrie GI Associates · Janssen Research & Development, LLC · NCT07577856 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · Royal Victoria Regional Health Centre ( Site 0233) · Merck Sharp & Dohme LLC · NCT06966700 A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Al
Phase 3 · Royal Victoria Regional Health Centre ( Site 0615) · Merck Sharp & Dohme LLC · NCT06952504 Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NA · Royal Victoria Regional Health Centre · University Health Network, Toronto · NCT05592938 A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Phase 3 · Research Site · AstraZeneca · NCT06549595 A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · Research Site · AstraZeneca · NCT05774951 Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cel
Phase 3 · Royal Victoria Regional Health Centre · Gilead Sciences · NCT06801834 Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy
Phase N/A · Royal Victoria Regional Health Centre · Ontario Clinical Oncology Group (OCOG) · NCT05866458 A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Phase 2 · Centricity Research Barrie Endocrinology · Zucara Therapeutics Inc. · NCT05762107 Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Phase 2 · Royal Victoria Regional Health Centre · Canadian Cancer Trials Group · NCT06043427 Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Phase 3 · SimcoDerm Medical and Surgical Dermatology Center · Bristol-Myers Squibb · NCT07116967 A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Phase 3 · Royal Victoria Regional Health Centre · Ontario Clinical Oncology Group (OCOG) · NCT05417516

Look up another city

Look up another condition